Digital Health 150 lists most promising healthcare startups

There are a trove of new companies breaking into the healthcare space with new and innovative solutions. And many of these are well-funded to the tune of several million dollars through venture capital funding.

CB Insights listed 150 of the “most promising private companies” with new products and services in the healthcare space with its first-ever Digital Health 150. The companies were chosen from a pool of more than 5,000 and were assessed on several factors, such as patent activity, investor profile, sentiment analysis, market potential, tech novelty and more.

The group represents $17.5 billion in funding from more than 500 equity deals. The funding came from over 850 unique investors, with F-Prime Capital, New Enterprise Associates and Google Ventures being the most active investors. Of the selected companies, 116 were located in the U.S., while 17 were from Asia, 16 from Europe and 1 from Canada.

The most well-funded companies include:

  • Grail, a biotech company that seeks to detect cancer early––$1.6 billion in funding
  • Oscar Health, a tech-focused health insurance provider––$1.27 billion
  • We Doctor, a China-based tech-enabled healthcare solutions platform––$1 billion
  • 23andMe––$791 million
  • Babylon Health––$635 million
  • HeartFlow––$532 million
  • Tempus––$520 million
  • American Well––$507 million
  • Proteus Digital Health––$474 million
  • Bright Health––$440 million

See the full Digital Health 150 here.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.